Skip to main content
. 2015 Oct 12;6(38):40896–40906. doi: 10.18632/oncotarget.5683

Figure 2. Kaplan–Meier curves showing that, among GBMs, patients with both IDH mutation and MGMT promoter methylation exhibited the best prognosis; patients harboring either mutated IDH or methylated MGMT promoter exhibited intermediate prognosis; patients with wild-type IDH and unmethylated MGMT promoter exhibited the worst.

Figure 2